BTAI - CIK 0001720893
The table below shows BioXcel Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $28.41M | $29.85M | $65.22M | $193.72M | $232.97M | $213.12M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | $722.00K | $679.00K | $1.99M | $1.99M | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $44.69M |
| $37.39M |
| $72.14M |
| $202.87M |
| $236.81M |
| $217.06M |
| Property, plant & equipment | $175.00K | $475.00K | $784.00K | $1.08M | $1.29M | $1.27M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $44.92M | $38.34M | $73.70M | $205.85M | $239.44M | $219.94M |
| Accounts payable | $14.70M | $15.99M | $13.65M | $10.23M | $4.68M | $3.98M |
| Total current liabilities | $53.93M | $22.23M | $27.27M | $32.90M | $16.67M | $11.84M |
| Long-term debt | $84.66M | $102.51M | $100.60M | $93.05M | - | - |
| Total liabilities | $140.38M | $131.44M | $130.21M | $129.08M | $17.77M | $13.24M |
| Retained earnings | -$720.09M | -$650.20M | -$590.60M | -$411.55M | -$245.79M | -$138.86M |
| Total equity | -$95.46M | -$93.10M | -$56.51M | $76.78M | $221.67M | $206.70M |